BRPI0716455A2 - Desenvolvimento de componentes de vacina do vírus da dengue - Google Patents

Desenvolvimento de componentes de vacina do vírus da dengue

Info

Publication number: BRPI0716455A2
Authority: BR; Brazil
Prior art keywords: dengue virus; virus vaccine; vaccine components; components development; development
Prior art date: 2006-08-15

Application number

BRPI0716455-6A2A

Other languages

English (en)

Inventor

Stephen S Whitehead

Joseph E Blaney

Brian R Murphy

Original Assignee

Us Dept Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-15

Filing date

2007-08-15

Publication date

2014-03-04

2007-08-15 Application filed by Us Dept Health filed Critical Us Dept Health

2007-08-15 Priority to BR122020023372-9A priority Critical patent/BR122020023372B1/pt

2014-03-04 Publication of BRPI0716455A2 publication Critical patent/BRPI0716455A2/pt

2019-01-15 Publication of BRPI0716455A8 publication Critical patent/BRPI0716455A8/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BRPI0716455A 2006-08-15 2007-08-15 desenvolvimento de componentes de vacina do vírus da dengue BRPI0716455A8 (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR122020023372-9A BR122020023372B1 (pt)	2006-08-15	2007-08-15	Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US83772306P	2006-08-15	2006-08-15
PCT/US2007/076004 WO2008022196A2 (en)	2006-08-15	2007-08-15	Development of dengue virus vaccine components

Publications (2)

Publication Number	Publication Date
BRPI0716455A2 true BRPI0716455A2 (pt)	2014-03-04
BRPI0716455A8 BRPI0716455A8 (pt)	2019-01-15

Family

ID=39083099

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0716455A BRPI0716455A8 (pt)	2006-08-15	2007-08-15	desenvolvimento de componentes de vacina do vírus da dengue
BR122020023372-9A BR122020023372B1 (pt)	2006-08-15	2007-08-15	Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR122020023372-9A BR122020023372B1 (pt)	2006-08-15	2007-08-15	Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Country Status (15)

Country	Link
US (9)	USRE46042E1 (pt)
EP (2)	EP2054428B9 (pt)
CN (2)	CN101657463B (pt)
AU (1)	AU2007285929B2 (pt)
BR (2)	BRPI0716455A8 (pt)
CA (2)	CA2661296C (pt)
CY (1)	CY1118003T1 (pt)
DK (2)	DK2589602T3 (pt)
ES (1)	ES2585553T3 (pt)
HU (1)	HUE029333T2 (pt)
LT (1)	LT2589602T (pt)
PL (1)	PL2589602T3 (pt)
PT (1)	PT2589602T (pt)
SI (1)	SI2589602T1 (pt)
WO (1)	WO2008022196A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2472468C (en) *	2002-01-10	2015-11-24	Alexander G. Pletnev	Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
HUE037330T2 (hu) *	2002-05-03	2018-08-28	The Government Of The Us Secretary Department Of Health And Human Services	rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
DK2589602T3 (en)	2006-08-15	2016-07-25	The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of	Development of dengue virus vaccine components
US8968996B2 (en)	2009-06-01	2015-03-03	Takeda Vaccines, Inc.	Compositions and methods for rapid immunization against dengue virus
US9211323B2 (en) *	2009-06-01	2015-12-15	Takeda Vaccines, Inc.	Compositions and methods for administration of vaccines against dengue virus
US8895028B2 (en)	2012-07-20	2014-11-25	Arbovax, Inc.	Methods and compositions for dengue virus 3 (DV3) infectious clone
JP2016504315A (ja)	2012-12-14	2016-02-12	タケダワクチン, インコーポレイテッドTakeda Vaccines, Inc.	三価デングウイルス製剤に関する組成物、投与方法および使用
CA3177572C (en) *	2013-03-15	2026-02-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Compositions and methods for dengue virus chimeric constructs in vaccines
MX366154B (es)	2013-06-21	2019-06-28	Merck Sharp & Dohme	Composiciones de vacuna del virus del dengue y metodos de uso de las mismas.
MX2017005524A (es) *	2014-11-02	2018-01-26	Univ North Carolina Chapel Hill	Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico.
MY192543A (en) *	2014-12-22	2022-08-26	Merck Sharp & Dohme	Dengue virus vaccine compositions and methods of use thereof
WO2017004567A1 (en)	2015-07-02	2017-01-05	PrimeVax Immuno-Oncology, Inc.	Compositions and methods for combination therapy with dengue virus and dendritic cells
MX2018003757A (es)	2015-09-26	2018-09-21	Primevax Immuno Oncology Inc	Composiciones y metodos para producir celulas dendriticas.
US11123420B2 (en) *	2015-09-30	2021-09-21	Panacea Biotec Limited	Stable live attenuated recombinant dengue vaccine
CN109152828A (zh)	2016-03-11	2019-01-04	美国政府(由卫生和人类服务部的部长所代表)	减毒活zika病毒疫苗
JP2020500847A (ja) *	2016-11-16	2020-01-16	プライムヴァックスイミュノ−オンコロジー，インク．	癌の処置のための併用免疫療法
EP3565567A4 (en)	2017-01-04	2020-07-29	Primevax Immuno-Oncology, Inc.	COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
WO2018129160A1 (en)	2017-01-06	2018-07-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Live attenuated flavivirus vaccines and methods of using and making same
CA3053289A1 (en) *	2017-02-14	2018-08-23	Xuping XIE	Live attenuated zika virus with 3'utr deletion, vaccine containing and use thereof
US10240130B2 (en)	2017-02-15	2019-03-26	The Board Of Regents Of The University Of Texas System	CDNA clone-launched platform for high-yield production of inactivated zika virus
US20200390877A1 (en)	2017-12-07	2020-12-17	Merck Sharp & Dohme Corp.	Formulations of dengue virus vaccine compositions
MX2022001742A (es)	2019-08-16	2022-04-07	Takeda Vaccines Inc	Metodos para prevenir el dengue y la hepatitis a.
WO2022182835A1 (en) *	2021-02-26	2022-09-01	Duke University	Compositions for and methods of improving gene therapy
US20240150729A1 (en) *	2021-03-19	2024-05-09	Merck Sharp & Dohme Llc	A closed-system upstream manufacturing process for dengue virus production
JP2025508605A (ja) *	2022-02-22	2025-03-26	フートルバイオエルティーディーエー．	次世代ｍＲＮＡワクチン
WO2025072259A1 (en)	2023-09-25	2025-04-03	Takeda Vaccines, Inc.	Coadministration of tetravalent dengue vaccine with hpv vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6184024B1 (en) *	1988-07-14	2001-02-06	The United States Of America As Represented By The Department Of Health And Human Services	Chimeric and/or growth-restricted flaviviruses
HUE037330T2 (hu) *	2002-05-03	2018-08-28	The Government Of The Us Secretary Department Of Health And Human Services	rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
EP1761277A1 (en) *	2004-06-14	2007-03-14	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	West nile viruses with mutations in the 3' terminal stem and loop secondary structure for use as live virus vaccines
DK2589602T3 (en) *	2006-08-15	2016-07-25	The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of	Development of dengue virus vaccine components

2007
- 2007-08-15 DK DK12182319.9T patent/DK2589602T3/en active
- 2007-08-15 WO PCT/US2007/076004 patent/WO2008022196A2/en not_active Ceased
- 2007-08-15 BR BRPI0716455A patent/BRPI0716455A8/pt not_active Application Discontinuation
- 2007-08-15 SI SI200731800A patent/SI2589602T1/sl unknown
- 2007-08-15 ES ES12182319.9T patent/ES2585553T3/es active Active
- 2007-08-15 LT LTEP12182319.9T patent/LT2589602T/lt unknown
- 2007-08-15 CN CN2007800341894A patent/CN101657463B/zh active Active
- 2007-08-15 PL PL12182319.9T patent/PL2589602T3/pl unknown
- 2007-08-15 CA CA2661296A patent/CA2661296C/en active Active
- 2007-08-15 PT PT121823199T patent/PT2589602T/pt unknown
- 2007-08-15 DK DK07840969.5T patent/DK2054428T3/da active
- 2007-08-15 US US13/895,908 patent/USRE46042E1/en active Active
- 2007-08-15 CN CN201310349675.2A patent/CN103602689B/zh active Active
- 2007-08-15 US US12/376,756 patent/US8337860B2/en not_active Ceased
- 2007-08-15 BR BR122020023372-9A patent/BR122020023372B1/pt active IP Right Grant
- 2007-08-15 HU HUE12182319A patent/HUE029333T2/en unknown
- 2007-08-15 AU AU2007285929A patent/AU2007285929B2/en active Active
- 2007-08-15 EP EP07840969.5A patent/EP2054428B9/en active Active
- 2007-08-15 EP EP12182319.9A patent/EP2589602B1/en active Active
- 2007-08-15 CA CA3004991A patent/CA3004991C/en active Active
2012
- 2012-12-03 US US13/692,557 patent/US9090873B2/en active Active
2015
- 2015-06-17 US US14/742,533 patent/US10160957B2/en active Active
2016
- 2016-07-06 CY CY20161100635T patent/CY1118003T1/el unknown
2018
- 2018-10-29 US US16/173,217 patent/US10724007B2/en active Active
2020
- 2020-06-25 US US16/912,359 patent/US11332722B2/en active Active
2022
- 2022-04-19 US US17/724,037 patent/US11746335B2/en active Active
2023
- 2023-07-19 US US18/355,265 patent/US12203100B2/en active Active
2024
- 2024-12-16 US US18/982,378 patent/US20250236848A1/en active Pending

Also Published As

Publication number	Publication date
LT2589602T (lt)	2016-10-10
US9090873B2 (en)	2015-07-28
US10724007B2 (en)	2020-07-28
WO2008022196A3 (en)	2009-03-12
CN101657463B (zh)	2013-09-18
US20130089567A1 (en)	2013-04-11
EP2589602A2 (en)	2013-05-08
US20240084269A1 (en)	2024-03-14
US20200318083A1 (en)	2020-10-08
AU2007285929A1 (en)	2008-02-21
BR122020023372B1 (pt)	2021-11-30
USRE46042E1 (en)	2016-06-28
CN103602689A (zh)	2014-02-26
EP2054428B9 (en)	2013-11-13
US20250236848A1 (en)	2025-07-24
US12203100B2 (en)	2025-01-21
AU2007285929A2 (en)	2009-04-23
BRPI0716455A8 (pt)	2019-01-15
US8337860B2 (en)	2012-12-25
US11332722B2 (en)	2022-05-17
US20190119654A1 (en)	2019-04-25
SI2589602T1 (sl)	2016-08-31
CA3004991A1 (en)	2008-02-21
US10160957B2 (en)	2018-12-25
CA2661296A1 (en)	2008-02-21
DK2589602T3 (en)	2016-07-25
EP2589602A3 (en)	2013-10-09
AU2007285929B2 (en)	2013-09-05
PT2589602T (pt)	2016-07-13
HUE029333T2 (en)	2017-03-28
CY1118003T1 (el)	2017-05-17
CA3004991C (en)	2022-08-30
PL2589602T3 (pl)	2016-11-30
CN103602689B (zh)	2016-08-24
US11746335B2 (en)	2023-09-05
EP2589602B1 (en)	2016-04-06
WO2008022196A2 (en)	2008-02-21
CA2661296C (en)	2018-06-26
EP2054428A2 (en)	2009-05-06
CN101657463A (zh)	2010-02-24
ES2585553T3 (es)	2016-10-06
US20100104598A1 (en)	2010-04-29
DK2054428T3 (da)	2013-08-26
US20220251521A1 (en)	2022-08-11
EP2054428B1 (en)	2013-06-05
US20180171308A1 (en)	2018-06-21

Legal Events

Date	Code	Title	Description
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-12-04	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-05-19	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-08-18	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-06-08	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-09-28	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-12-14	B12B	Appeal against refusal [chapter 12.2 patent gazette]

Publication	Publication Date	Title
NO2021010I1 (no)	2021-03-01	telostritat ethyl
PT2589602T (pt)	2016-07-13	Desenvolvimento de componentes de vacina contra o vírus da dengue
BRPI0716483A2 (pt)	2016-06-07	inibidores do vírus da hepatite c
ATE450271T1 (de)	2009-12-15	Impfstoff
DK3192874T3 (da)	2019-12-16	Virusoprensning
DK1968631T3 (da)	2015-06-15	Vaccine
PL2281830T3 (pl)	2017-06-30	Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
DK2066354T3 (da)	2013-05-27	Norovirus vaccine formuleringer
DK1926496T3 (da)	2013-09-30	PCV-2-vaccine
CR10571A (es)	2009-05-14	Vacuna virica recombinante
DK2051744T3 (da)	2014-02-03	Steriliseringsanordning
DK2069335T3 (da)	2013-02-18	Pyridin-3-ylderivater som immunomoduleringsmidler
BRPI0716193A2 (pt)	2013-11-12	Replicon derivado de potexvírus
BRPI0821252A2 (pt)	2015-06-16	Anticorpos ao vírus da hepatite c
BRPI0821034A2 (pt)	2015-06-16	Vírus influenza modificado
EP2198016A4 (en)	2011-04-20	ADENO ASSOCIATED SWINE VIRUS
EP1917040A4 (en)	2012-12-12	POLYVALENT VACCINE
EP2065801A4 (en)	2013-01-02	EMULATOR
DE502007001364D1 (de)	2009-10-01	Tevorrichtung
ZA200809056B (en)	2010-01-27	Influenza virus vaccine
DK2043682T3 (da)	2014-06-02	Influenzavaccine
DE602006020744D1 (de)	2011-04-28	Fertigspritze
EP2061502A4 (en)	2010-10-20	CARBOHYDRATE-BASED VACCINES FOR HLV
DE602007000237D1 (de)	2008-12-24	Projektionsvorrichtung
BRPI0923034A2 (pt)	2015-12-15	terapia de combinação para virus da hepatite c